These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 37369234)
1. The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Grymonprez M; Petrovic M; De Backer TL; Steurbaut S; Lahousse L Thromb Haemost; 2024 Feb; 124(2):135-148. PubMed ID: 37369234 [TBL] [Abstract][Full Text] [Related]
2. Impact of frailty on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a nationwide cohort study. Grymonprez M; Petrovic M; De Backer TL; Steurbaut S; Lahousse L Eur Heart J Qual Care Clin Outcomes; 2024 Jan; 10(1):55-65. PubMed ID: 36941126 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses. Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628 [TBL] [Abstract][Full Text] [Related]
4. Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists: a Belgian nationwide cohort study. Grymonprez M; Petrovic M; De Backer TL; Ikram MA; Steurbaut S; Lahousse L Age Ageing; 2023 Mar; 52(3):. PubMed ID: 36934339 [TBL] [Abstract][Full Text] [Related]
5. Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study. Grymonprez M; De Backer TL; Bertels X; Steurbaut S; Lahousse L Front Pharmacol; 2023; 14():1125576. PubMed ID: 36817122 [No Abstract] [Full Text] [Related]
6. Clinical outcomes in patients with atrial fibrillation and a history of falls using non-vitamin K antagonist oral anticoagulants: A nationwide cohort study. Grymonprez M; Petrovic M; De Backer TL; Steurbaut S; Lahousse L Int J Cardiol Heart Vasc; 2023 Aug; 47():101223. PubMed ID: 37252193 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Skjøth F; Larsen TB; Rasmussen LH; Lip GY Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485 [TBL] [Abstract][Full Text] [Related]
8. The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis. Yang KT; Sun WC; Tsai TJ; Tsay FW; Chen WC; Cheng JS Int J Environ Res Public Health; 2020 Dec; 18(1):. PubMed ID: 33375495 [No Abstract] [Full Text] [Related]
9. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370 [TBL] [Abstract][Full Text] [Related]
10. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation. Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients. Silverio A; Di Maio M; Prota C; De Angelis E; Radano I; Citro R; Carrizzo A; Ciccarelli M; Vecchione C; Capodanno D; Galasso G Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f20-f29. PubMed ID: 31830264 [TBL] [Abstract][Full Text] [Related]
12. Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis. Xu W; Lv M; Wu S; Jiang S; Zeng Z; Fang Z; Qian J; Chen M; Chen J; Zhang J Cardiovasc Drugs Ther; 2023 Apr; 37(2):363-377. PubMed ID: 34436708 [TBL] [Abstract][Full Text] [Related]
13. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation. Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801 [No Abstract] [Full Text] [Related]
14. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study. Van Ganse E; Danchin N; Mahé I; Hanon O; Jacoud F; Nolin M; Dalon F; Lefevre C; Cotté FE; Gollety S; Falissard B; Belhassen M; Steg PG Stroke; 2020 Jul; 51(7):2066-2075. PubMed ID: 32539675 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation. Lee SR; Choi EK; Kwon S; Han KD; Jung JH; Cha MJ; Oh S; Lip GYH Stroke; 2019 Aug; 50(8):2245-2249. PubMed ID: 31208303 [TBL] [Abstract][Full Text] [Related]
16. Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. Hohnloser SH; Basic E; Nabauer M Clin Res Cardiol; 2017 Aug; 106(8):618-628. PubMed ID: 28293797 [TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243 [No Abstract] [Full Text] [Related]
19. Effectiveness and safety of secondary prevention of non-vitamin K oral anticoagulants use by drug type in Asian patients. Nam KW; Kwon HM; Lee YS; Won SH; Moon HS Int J Stroke; 2023 Oct; 18(8):927-936. PubMed ID: 37154599 [TBL] [Abstract][Full Text] [Related]
20. Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation Using P-gp and/or CYP450-Interacting Drugs: a Systematic Review and Meta-analysis. Grymonprez M; Vanspranghe K; Steurbaut S; De Backer TL; Lahousse L Cardiovasc Drugs Ther; 2023 Aug; 37(4):781-791. PubMed ID: 34637052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]